发明名称
摘要 Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in "suicide" of viral-infected cells (but not uninfected cells) in order to limit viral propagation. While any of the enzymes in the relevant metabolic pathway can be selected, pivotal enzymes at key control points in these metabolic pathways are preferred as candidate antiviral drug targets. Inhibitors of these enzymes are used to reverse, or redirect, the effects of the viral infection. Drug candidates are tested for antiviral activity using screening assays in vitro and host cells, as well as in animal models.; Animal models are then used to test efficacy of candidate compounds in preventing and treating viral infections. The antiviral activity of enzyme inhibitors is demonstrated.
申请公布号 JP2010538968(A) 申请公布日期 2010.12.16
申请号 JP20100510373 申请日期 2008.06.02
申请人 发明人
分类号 A61K31/045;A61K31/085;A61K31/122;A61K31/136;A61K31/192;A61K31/194;A61K31/198;A61K31/216;A61K31/22;A61K31/222;A61K31/223;A61K31/265;A61K31/336;A61K31/341;A61K31/353;A61K31/365;A61K31/366;A61K31/381;A61K31/395;A61K31/4015;A61K31/403;A61K31/41;A61K31/416;A61K31/4178;A61K31/4196;A61K31/42;A61K31/421;A61K31/426;A61K31/427;A61K31/428;A61K31/44;A61K31/4439;A61K31/444;A61K31/4545;A61K31/4706;A61K31/473;A61K31/496;A61K31/501;A61K31/506;A61K31/519;A61K31/52;A61K31/53;A61K31/5377;A61K31/661;A61K31/663;A61K31/7048;A61K31/7076;A61K45/00;A61P1/16;A61P31/12;A61P31/14;A61P31/16;A61P31/20;A61P31/22;A61P35/02;A61P43/00;C07K5/06 主分类号 A61K31/045
代理机构 代理人
主权项
地址